查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529662

美国氯胺酮诊所市场规模、份额、趋势分析报告：按治疗、治疗方法和细分市场预测，2024-2030 年

U.S. Ketamine Clinics Market Size, Share, & Trends Analysis Report By Treatment (Depression, Anxiety, PTSD, Others), By Therapy (On-site Therapy, Online Therapy), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国氯胺酮诊所市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国氯胺酮诊所市场规模预计将达到69亿美元，2024年至2030年复合年增长率为10.60%。

据 SAMHSA 称，到 2022 年，大约 19.86% 的成年人（约 5000 万人）将患有某种形式的精神疾病，4.91% 的人将患有严重的精神疾病。精神疾病的盛行率因州而异，从新泽西州的 16.37% 到犹他州的 26.86%。

此外，COVID-19 大流行对成人心理健康产生了负面影响，导致对创新治疗的需求增加。根据凯撒家庭基金会的调查，2021 年 2 月，39.3% 的美国成年人报告有焦虑或忧郁症症状，较大流行前水准显着增加。心理健康问题的增加产生了对有效、快速治疗的需求，进一步推动了美国市场的成长。

此外，当地服务提供者与在美国提供氯胺酮治疗的领先氯胺酮诊所提供者的日益整合预计也将增加市场机会。市场参与企业正在采取各种策略措施来增强他们的能力，提高他们的能力，并扩大他们的服务组合。例如，2023 年 10 月，Nue Life Health 被一家专门从事迷幻医学的风险工作室收购。此次收购符合工作室推进精神健康领域创新治疗的使命，特别是透过使用迷幻疗法。

美国氯胺酮诊所市场报告亮点

  • 依治疗方式划分，忧郁症细分市场在 2023 年占据最大市场占有率。这是由于越来越多的美国成年人患有严重的忧郁症。
  • 从治疗方法来看，随着氯胺酮治疗精神疾病在美国获得接受，导致诊所扩张，现场治疗领域在 2023 年占据了最大的市场占有率。
  • 2024 年 2 月，Avesta Ketamine and Wellness 与退伍军人事务部 (VA) 建立合作伙伴关係，为马里兰州、贝塞斯达、北维吉尼亚和华盛顿特区的退伍军人提供免费氯胺酮治疗。该倡议预计将帮助患有药物滥用障碍、慢性疼痛、焦虑、创伤后压力症候群和抗治疗性忧郁症的退伍军人。

目录

第一章调查方法与范围

第二章执行概述

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势及展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 法律规范
  • 商业环境分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章治疗业务分析

  • 美国氯胺酮诊所市场：治疗方法变异分析
  • 美国氯胺酮诊所市场：治疗方法细分仪表板
  • 2023 年和 2030 年治疗方法趋势和市场占有率分析
  • 依治疗方法
  • 忧郁症
    • 忧郁症市场，2018-2030
  • 焦虑
    • 焦虑的市场，2018-2030
  • PTSD
    • 创伤后压力症候群市场，2018-2030
  • 其他的
    • 其他市场，2018-2030

第五章治疗业务分析

  • 美国氯胺酮诊所市场：治疗方法变异分析
  • 美国氯胺酮诊所市场：治疗方法细分仪表板
  • 2023 年和 2030 年治疗方法趋势和市场占有率分析
  • 依治疗方法
  • 现场治疗方法
  • 线上治疗方法

第六章 竞争状况

  • 公司分类
  • 公司市场分析
  • 策略规划
    • 伙伴关係/协作/联盟
    • 新服务开始了
    • 併购
    • 其他的
  • 公司简介/上市公司
    • NY Ketamine Infusions
    • Stella MSO LLC dba Field Trip Health
    • Ketamine Clinics Los Angeles
    • Klarity Clinic（Tebra Inc.）
    • Vitalitas Denver Ketamine Infusion Center
    • Mindbloom, Inc.
    • Nue Life Health（NueCo Holdings, PBC）
    • Better U, Inc.
    • Innerwell（KBS, Inc.）
    • Klarisana Health
Product Code: GVR-4-68040-092-1

U.S. Ketamine Clinics Market Growth & Trends:

The U.S. ketamine clinics market size is anticipated to reach USD 6.90 billion by 2030, exhibiting a CAGR of 10.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market's growth can be attributed to the increase in mental health awareness, the ongoing opioid crisis, and an increasing number of ketamine clinics across the U.S. According to SAMHSA, in 2022, about 19.86% of adults, which is nearly 50 million people, had some form of mental illness, with 4.91% experiencing severe mental health conditions. The prevalence of mental illness varied by state, ranging from 16.37% in New Jersey to 26.86% in Utah.

Moreover, the COVID-19 pandemic had a negative impact on the mental health of adults, leading to an increased demand for innovative treatments. A survey by the Kaiser Family Foundation found that 39.3% of adults in the U.S. reported symptoms of anxiety or depressive disorder in February 2021, a significant increase from pre-pandemic levels. This increase in mental health issues has created the need for effective and rapid treatments, further driving the growth of the market in the U.S.

Moreover, the growing consolidation of local service providers with major ketamine clinic providers to offer ketamine treatments in the U.S. is expected to increase opportunities in the market. Market players are undertaking various strategic initiatives to increase their capabilities, improve competencies, and expand their service portfolios. For instance, in October 2023[, Nue Life Health was acquired by a venture studio specializing in psychedelic healthcare. This acquisition aligned with the studio's mission to advance innovative treatments in the mental wellness space, particularly through the use of psychedelic therapies.

U.S. Ketamine Clinics Market Report Highlights:

  • Based on treatment, the depression segment held the largest market share in 2023. This can be attributed to the growing number of American adults burdened with severe major depression.
  • Based on therapy, the on-site therapy segment dominated the market with the largest market share in 2023 owing to the growing acceptance of ketamine therapy for mental health disorders which has led to an expansion of clinics in the U.S.
  • In February 2024, Avesta Ketamine and Wellness entered into a partnership with Veteran Affairs (VA) to provide free ketamine therapy to veterans across Maryland, Bethesda, Northern Virginia, and Washington DC. This initiative was expected to help veterans with substance abuse disorder, chronic pain, anxiety, PTSD, and treatment-resistant depression.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Volume Price Analysis
  • 1.8. Objectives
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. U.S. Ketamine Clinics Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Growing demand for effective mental health treatments
      • 3.3.1.2. Growing acceptance of ketamine's therapeutic potential
      • 3.3.1.3. Increasing investment and partnerships in ketamine clinics
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Potential side effects and risks associated with ketamine therapy
      • 3.3.2.2. Easy accessibility for alternative treatments
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis

Chapter 4. Treatment Business Analysis

  • 4.1. U.S. Ketamine Clinics Market: Treatment Movement Analysis
  • 4.2. U.S. Ketamine Clinics Market: Treatment Segment Dashboard
  • 4.3. Treatment Movement & Market Share Analysis, 2023 & 2030
  • 4.4. U.S. Ketamine Clinics Market Estimates & Forecast, by Treatment
  • 4.5. Depression
    • 4.5.1. Depression market, 2018 - 2030 (USD Million)
  • 4.6. Anxiety
    • 4.6.1. Anxiety market, 2018 - 2030 (USD Million)
  • 4.7. PTSD
    • 4.7.1. PTSD market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Therapy Business Analysis

  • 5.1. U.S. Ketamine Clinics Market: Therapy Movement Analysis
  • 5.2. U.S. Ketamine Clinics Market: Therapy Segment Dashboard
  • 5.3. Therapy Movement & Market Share Analysis, 2023 & 2030
  • 5.4. U.S. Ketamine Clinics Market Estimates & Forecast, by Therapy
  • 5.5. On-site Therapy
    • 5.5.1. On-site therapy market, 2018 - 2030 (USD Million)
  • 5.6. Online Therapy
    • 5.6.1. Online therapy market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Company Market Position Analysis
  • 6.3. Strategy Mapping
    • 6.3.1. Partnership/Collaboration/Alliance
    • 6.3.2. New Service Launch
    • 6.3.3. Mergers & Acquisitions
    • 6.3.4. Others
  • 6.4. Company Profiles/Listing
    • 6.4.1. NY Ketamine Infusions
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Service benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. Stella MSO LLC dba Field Trip Health
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Service benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Ketamine Clinics Los Angeles
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Service benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Klarity Clinic (Tebra Inc.)
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Service benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Vitalitas Denver Ketamine Infusion Center
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Service benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. Mindbloom, Inc.
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Service benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Nue Life Health (NueCo Holdings, P.B.C.)
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Service benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Better U, Inc.
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Service benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. Innerwell (KBS, Inc.)
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Service benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Klarisana Health
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Service benchmarking
      • 6.4.10.4. Strategic initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. ketamine clinics market revenue estimates and forecast, by treatment, 2018 - 2030 (USD Million)
  • Table 4. U.S. ketamine clinics market revenue estimates and forecast, by therapy, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. ketamine clinics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Treatment & therapy segment outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. ketamine clinics market: Market dynamics
  • Fig. 13 U.S. ketamine clinics market: Porter's analysis
  • Fig. 14 U.S. ketamine clinics market: PESTLE analysis
  • Fig. 15 U.S. ketamine clinics market: Treatment segment dashboard
  • Fig. 16 U.S. ketamine clinics market: Treatment movement share analysis
  • Fig. 17 Depression market, 2018 - 2030 (USD Million)
  • Fig. 18 Anxiety market, 2018 - 2030 (USD Million)
  • Fig. 19 PTSD market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. ketamine clinics market: Therapy segment dashboard
  • Fig. 22 U.S. ketamine clinics market: Therapy movement share analysis
  • Fig. 23 On-site therapy market, 2018 - 2030 (USD Million)
  • Fig. 24 Online therapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Company categorization
  • Fig. 26 Company market position analysis
  • Fig. 27 Strategic framework